The design and synthesis of selective prostaglandin analogs as bone anabolic agents for the potential treatment of osteoporosis.
A series of prostaglandins selective for the human FP receptor have been synthesized and evaluated as potential therapeutics for the treatment of osteoporosis. The compounds proved to be potent (nanomolar binding affinity) and selective (> 100x) ligands for the human FP receptor in vitro, and increased bone volume in the ovariectomized rat in vivo.
Soper
David Lindsey
DL
Procter and Gamble Pharmaceuticals, 8700 Mason-Montgomery Road, Mason, Ohio 45040-9317, USA.
Wang
Yili
Y
De
Biswanath
B
deLong
Mitchell Anthony
MA
Dirr
Michelle Jeanine
MJ
Soehner
Michele Elaine
ME
Lundy
Mark Walden
MW
Mieling
Glen Edward
GE
Wos
John August
JA
D001842:Bone and Bones / Q000187:drug effects / Q000502:physiology* / Q000503:physiopathology; D015195:Drug Design; D006801:Humans; D008958:Models, Molecular; D015394:Molecular Structure; D010024:Osteoporosis / Q000188:drug therapy*; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000138:chemical synthesis* / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; C006326:fluprostenol